Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARMAINE IFEOMA EMELIFE

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1811987209
CMS profile
172955
Location
EAST POINT, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,104.29

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,951.09 11
Food and Beverage $1,123.25 18
Education $29.95 7

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,978.19 25
Lilly USA, LLC $46.25 2
Travere Therapeutics, Inc. $29.95 7
Otsuka America Pharmaceutical, Inc. $27.95 1
Amgen Inc. $21.95 1

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARMAINE IFEOMA EMELIFE

NPI 1811987209 · CMS profile ID 172955

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

EAST POINT, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811987209?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARMAINE IFEOMA EMELIFE, NPI 1811987209, CMS profile ID 172955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811987209?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHARMAINE IFEOMA EMELIFE, NPI 1811987209, CMS profile ID 172955. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811987209?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHARMAINE IFEOMA EMELIFE, NPI 1811987209, CMS profile ID 172955, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1811987209?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $3,104.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $25.8710/09/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155177851 CMS
Travere Therapeutics, Inc. $0.3709/03/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906543 CMS
Travere Therapeutics, Inc. $3.0809/03/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906559 CMS
Otsuka America Pharmaceutical, Inc. $27.9507/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118889348 CMS
Travere Therapeutics, Inc. $0.3706/27/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906539 CMS
Travere Therapeutics, Inc. $3.0806/27/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906555 CMS
AstraZeneca Pharmaceuticals LP $39.7306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104226985 CMS
AstraZeneca Pharmaceuticals LP $34.7706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104281281 CMS
AstraZeneca Pharmaceuticals LP $49.6706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104384415 CMS
AstraZeneca Pharmaceuticals LP $277.2006/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104413369 CMS
AstraZeneca Pharmaceuticals LP $34.7706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104550034 CMS
AstraZeneca Pharmaceuticals LP $134.0906/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104593860 CMS
AstraZeneca Pharmaceuticals LP $48.2906/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104621340 CMS
AstraZeneca Pharmaceuticals LP $64.1506/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105557190 CMS
AstraZeneca Pharmaceuticals LP $205.1806/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105631045 CMS
AstraZeneca Pharmaceuticals LP $205.1806/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105758555 CMS
AstraZeneca Pharmaceuticals LP $134.0906/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105877325 CMS
AstraZeneca Pharmaceuticals LP $200.0005/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105898446 CMS
Lilly USA, LLC $20.3804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136103624 CMS
Amgen Inc. $21.9503/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111569957 CMS
Travere Therapeutics, Inc. $3.0803/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906551 CMS
Travere Therapeutics, Inc. $16.8903/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906563 CMS
AstraZeneca Pharmaceuticals LP $57.1902/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104460722 CMS
AstraZeneca Pharmaceuticals LP $54.0902/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104478062 CMS
AstraZeneca Pharmaceuticals LP $72.9402/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104555366 CMS
AstraZeneca Pharmaceuticals LP $228.1002/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104561400 CMS
AstraZeneca Pharmaceuticals LP $53.7702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104690784 CMS
AstraZeneca Pharmaceuticals LP $135.0002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104730921 CMS
AstraZeneca Pharmaceuticals LP $53.7702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105523631 CMS
AstraZeneca Pharmaceuticals LP $135.0002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105572807 CMS
AstraZeneca Pharmaceuticals LP $70.7402/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105637982 CMS
AstraZeneca Pharmaceuticals LP $228.1002/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105748443 CMS
AstraZeneca Pharmaceuticals LP $60.5902/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105763486 CMS
AstraZeneca Pharmaceuticals LP $50.5702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105816689 CMS
AstraZeneca Pharmaceuticals LP $351.2102/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105884667 CMS
Travere Therapeutics, Inc. $3.0801/30/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149906547 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $203.16 8
PY2020 $18.41 1
PY2021 $129.32 2
PY2022 $445.81 14
PY2023 $382.76 10
PY2024 $3,104.29 36
PY2025 $365.84 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $317,632.67 11
PY2024 Principal investigator $221,424.03 12
PY2023 Principal investigator $20,330.95 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $113,866.26 07/11/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185548797
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,961.60 02/28/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185548795
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,816.00 02/21/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225403395
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,228.00 02/19/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225405216
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $120.00 01/31/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411802
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,500.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411762
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411788
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $60.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411800
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $214.00 01/13/2025 Non-covered Recipient Entity
Panoramic Science Llc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411818
Principal investigator 1 AstraZeneca Pharmaceuticals LP $131,595.68 01/03/2025 Non-covered Recipient Entity
PANORAMIC HEALTH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185548793
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $52,211.13 01/01/2025 Non-covered Recipient Entity
SOUTHEAST KIDNEY ASSOCIATES
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214123636